BioSpace News Archive

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to NERLYNX® (neratinib) for the treatment of breast cancer patients with brain metastases.

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Baird 2019 Global Healthcare Conference in New York on Thursday, September 5th, at 10:15 a.m. EDT, and at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 10th, at 10:00 a.m. EDT.

On September 1, Texas Gov. Greg Abbott signed into law a bill that eliminates the requirement for patients to obtain a doctor’s prescription prior to seeking treatment from a licensed physical therapist.

Willow Biosciences Inc. is pleased to announce it has engaged The Howard Group as its capital markets communications advisor to assist with both traditional and online initiatives targeting institutional and retail investing groups as well as the larger investment community.

Globe Life Inc. announced that its Board of Directors has declared a quarterly dividend of $0.1725 per share on all of the outstanding common stock of the Company held of record as of the close of business of the Company’s transfer agent on October 4, 2019.

Contacts and support to help diabetes care providers and patients prepare urgently

Gregory Robinson, Ph.D., Appointed to Chief Scientific Officer Co-Founder Michael McKenna, M.D., Expands Role to Full-Time Chief Medical Officer

Neovasc, Inc. announced that its Neovasc Reducer™ (the “Reducer”) for the treatment of patients suffering from refractory angina has been added to the European Society of Cardiology (ESC) Practice Guidelines.

Company’s head of intellectual property recognized by Intellectual Asset Management as a global IP strategy leader for fifth consecutive year

The Leukemia & Lymphoma Society of Canada (LLSC) kicked off Blood Cancer Awareness Month and announced today it will invest over $4 million in research projects that take on the toughest challenges in blood cancer.